Affiliation:
1. SmithKline Beecham Pharmaceuticals, Betchworth, Surrey, United Kingdom.
Abstract
Clavulanic acid, sulbactam, and tazobactam are inhibitors of a variety of plasmid-mediated beta-lactamases. However, inhibition data for these three inhibitors with a wide range of different plasmid-mediated beta-lactamases have not yet been compared under the same experimental conditions. A number of groups have inferred that clavulanic acid inhibits extended-spectrum TEM and SHV beta-lactamases, but inhibition data have rarely been published. In this study, the 50% inhibitory concentrations of these three beta-lactamase inhibitors for 35 plasmid-mediated beta-lactamases have been determined. Of these 35 beta-lactamases, 20 were extended-spectrum TEM- or SHV-derived beta-lactamases. The other 15 enzymes were conventional-spectrum beta-lactamases such as TEM-1 and SHV-1. Clavulanic acid was a more potent inhibitor than sulbactam for 32 of the 35 plasmid-mediated beta-lactamases tested. In particular, clavulanic acid was 60 and 580 times more potent than sulbactam against TEM-1 and SHV-1, respectively, currently the two most clinically prevalent gram-negative plasmid-mediated beta-lactamases. Statistical analysis of the data of the 50% inhibitory concentrations showed that clavulanic acid was 20 times more active overall than sulbactam against the conventional-spectrum enzymes. In addition, clavulanic acid was 14 times more potent than sulbactam at inhibiting the extended-spectrum enzymes. Tazobactam also showed significantly greater activity than sulbactam against the two groups of beta-lactamases. There were no significant differences between the overall activities of tazobactam and clavulanic acid against the extended-spectrum TEM and SHV enzymes and conventional-spectrum enzymes, although differences in their inhibition profiles were observed.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference37 articles.
1. Amyes S. G. B. 1988. Plasmid mediated f-lactamases: relative clinical importance p. 31-50. In D. Livermore (ed.) 1-lactamases: current perspectives. Thermacom Ltd. Winchester United Kingdom.
2. Comparative activities of the P-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin;Aronof S. C.;Antimicrob. Agents Chemother.,1984
3. Novel R-factor borne P-lactamase of E. coli conferring resistance to cephalosporins;Bauernfeind A.;Infection,1987
4. Characterization of ,B-lactamases;Bush K.;Antimicrob. Agents Chemother.,1989
5. Kinetic interaction of tazobactam with ,-lactamases from all major structural classes;Bush K.;Antimicrob. Agents Chemother.,1993
Cited by
136 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献